logo SBA

ETD

Digital archive of theses discussed at the University of Pisa

 

Thesis etd-10072023-143623


Thesis type
Tesi di specializzazione (4 anni)
Author
DEL GIUDICE, MARIA LIVIA
URN
etd-10072023-143623
Thesis title
Soluble B-Cell Maturation Antigen: role in short-term monitoring of differently treated Multiple Myeloma patients
Department
MEDICINA CLINICA E SPERIMENTALE
Course of study
EMATOLOGIA
Supervisors
relatore Prof. Buda, Gabriele
Keywords
  • B-cell maturation antigen
  • biomarker
  • multiple myeloma
  • sBCMA
Graduation session start date
06/11/2023
Availability
Withheld
Release date
06/11/2093
Summary
Multiple myeloma is a tumor of plasma cells and accounts for about 10% of all hematological malignancies. Its clinical course is characterized by periodic relapses over time, with an increasingly shorter progression-free interval with each evidence of recurrence. Despite the availability of more effective drugs and the improvement in overall survival rates compared with the past, it remains incurable. There is therefore a need for new therapies with new mechanisms of action, but also for new tools to assess the disease status and perhaps prevent clinical relapse, in order to meet the challenge that this disease still represents in the field of hematology. In general, biochemical markers are useful in multiple myeloma because they are inexpensive and non-invasive methods of assessment. sBCMA stands for soluble B-cell maturation antigen: it appears to be a very promising biomarker, because it can be detected in peripheral blood by low-cost methods. Our research aims to validate its significance in an unselected population of multiple myeloma patients undergoing life-saving treatments at different stages of the disease.
File